Immunohistochemical Expression of EGFR Oncoprotein and Its Prognostic Significance in Salivary Gland Carcinomas

Česká verzia

Authors: I. Stárek ¹; L. Kučerová ²; A. Skálová ³; M. Brož ¹; T. Bakaj ¹; A. Zapletalová ⁴; L. Hostička ⁵
Authors place of work: Klinika otorinolaryngologie a chirurgie hlavy a krku LF UP a FN, Olomouc ; přednosta prof. MUDr. I. Stárek, CSc. Ústav patologie, FN Olomouc ¹; přednosta doc. MUDr. M. Tichý, CSc. Ústav patologie, FN Plzeň ²; přednosta prof. MUDr. M. Michal Ústav lékařské biofyziky LF UP, Olomouc ³; přednostka doc. RNDr. H. Kolářová, CSc. Stomatologická klinika FN Plzeň ⁴; přednosta doc. MUDr. A. Zicha, CSc. ⁵
Published in the journal: Otorinolaryngol Foniatr, 60, 2011, No. 2, pp. 78-84.
Category: Original Article

Summary

Background:
To investigate the expression of EGFR oncoprotein in salivary gland carcinomas and to correlate it with the prognosis, T stage of the primary and its cervical metastases.

Methods:
Immunohistochemistry for EGFR protein was performed in 76 carcinomas, using formalin-fixed paraffin-embedded sections. For the evaluation of reactivity of tumor cells, a histoscore combining membranous staining intensity (scala no reaction, weak, moderate, strong) with the percentage of positive cells, namely 0 (no reaction or reaction in <10 % cells), 1+, 2+, 3+ (weak, moderate, strong in ≥ 10 % of cells) was applied. Prognostic correlation was performed in a subset of 55 patients in three different modes: I. 0 negative vs. 1+, 2+, and 3+ positive. II. 0, 1+ negative vs. 2+ and 3+ positive. III. 0, 1+, 2+ negative vs. 3+ positive. Univariate disease-specific survival curves were calculated by Kaplan-Meier method, the distributions were compared with the log-rank test. For the same modes, correlation between EGFR expression and the T stage of the primary and its cervical metastases was evaluated using Fisher’s exact test.

Results:
39.5 % (30/76) carcinomas were EGFR negative, 60,5 % (46/76) were positive, with the histoscore of the latter making 1+, 2+ and 3+ in 15 (32.6 %) (1+), 12 (26.1 %) and 19 (41.3 %) cases, respectively. In adenoid cystic, salivary duct and mucoepidermoid carcinoma and carcinoma ex pleomorphic adenoma the EGFR immunoreaction tested positive in 65.5 % (19/29), 47.8 % (11/23), 83.3 % (5/6) and 100 % (4/4) of cases, respectively. 80 % (4/5) of acinic cell carcinomas were scored with 0. Of other histopathologic entities, positive EGFR immunoreaction was recorded in undifferentiated carcinoma (2/2), malignant mixed tumour (1/2), adenocarcinoma NOS (1/1), papillary-cystic adenocarcinoma (1/1) and mammary analogue secretory carcinoma of salivary glands (1/1). One each small cell carcinoma and cribriform cystadenocarcinoma was EGFR negative. The disease-specific survival in EGFR positive carcinomas differed from that in EGFR negative ones, especially in modus II, but no statistic significance was recorded (p=0.073).

Conclusions:
Of all histopathological entities tested, carcinoma ex pleomorphic adenoma, undifferentiated carcinoma and adenocarcinoma NOS showed 100% immunoreactivity, the reaction of other histotypes was less frequent with a variable histoscore. We failed to demonstrate any statistical significance of EGFR expression for the prognosis, T stage and cervical metastases of salivary gland carcinomas.

Key words:
EGFR oncoprotein, salivary gland carcinoma, prognosis.

Zdroje

1. Agulnik, M., Cohen, E. W., Cohen, R. B. et al.: A phase II study of lapatinib in recurrent or metastatic EGFR and/or Erb2 expressing adenoid cystic and non-adenoid cystic malignant tumors of the salivary glands. J. Clin. Oncol., 25, 2007, s. 3987-3984.

2. Anzick, S. L., Chen, W. D., Park, Y. et al.: Unfavourable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Gen. Chrom. Cancer, 49, 2010, s. 59-69.

3. Dahse, R., Driemel, O., Schwarz, S. et al: Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas. Br. J. Cancer, 100, 2009, s. 623-625.

4. Dahse, R., Kromeyer-Hauschild, K., Berdnt, A. et al.: No indidence of BRAF mutations in salivary gland carcinomas – implications for anti-EGFR therapies. J. Biomed. Biotech. [online], 2009, 501736, [cit. 2011-01-19]. Dostupný z WWW: <10.1155/2009/501736>.

5. De Dosso, S., Mazzucchelli, L., Gheilmini, M. et al.: Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. Tumori, 95, 2009, s. 378-381.

6. Di Palma, S., Skálová, A., Vaněček, T. et al.: Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathol., 46, 2005, č. 2, s. 144-152.

7. Ettl, T., Schwarz, N., Hartmann, A. et al.: Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathol. 53, 2008, č. 5, s. 567-577.

8. Fan, Ch. Y., Melhem, M., Hosal, A. S. et al.: Expression of androgen receptor, epidermal growth factor, and transforming growth factor α in salivary duct carcinoma. Arch. Otolaryngol. Head Neck Surg., 127, 2001, s. 1075-1079.

9. Gibbons, M. D., Manne, U., Carroll, W. R. et al.: Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope, 111, 2001, s. 1373-1378.

10. Glisson, B. S., Blumenschein, F. M., Erasmus, J. et al.: Phase II trial of gefitinib in patients with incurable salivary gland cancer. Proc. Amer. Soc. Clin. Oncol., 23, 2005, s. 508, abs. 5532.

11. Grandis, J. R., Melhem, M. F., Gooding, W. E. et al.: Levels of TGFα and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Nat. Cancer Inst., 90, 1998, s. 824-832.

12. Hoyek-Gebeily, J., Nehmé, E., Aftimos, G. et al.: Mucoepidermoid carcinoma of salivary glands: the prognostic value of tumoral markers. Rev. Stomatol. Chir. Maxillofac., 108, 2007, č. 6, s. 482-488.

13. Kari, C., Chan, T. O., Rocha de Quadros, V. et al.: Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res., 63, 2003, č. 1, s. 1-5.

14. Katopodi, E., Patsouris, E., Papanikolaou, V. et al.: Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 95, 2003, s. 266-268.

15. Katori, H., Nozawa, A., Tsukuda, M.: Expression of epidermal growth factor receptor, transforming growth factor-α and Ki-67 in relationship to malignant transformation of pleomorphic adenoma. Acta Oto-Laryngol., 127, 2007, s.1207-1213.

16. Laurie, S. A., Licitra, L.: Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol., 24, 2006, s. 2673-2678.

17. Licitra, L., Locati, L. D., Potepan, P. et al.: Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional phase II study. J. Clin. Oncol., 24, 2006, č. 18S, part 1, s. 291, (abs. No. 5547).

18. Maiorano, E., Favia, G., Maisonnneuve, P. et al.: Prognostic implication of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. J. Pathol., 185, 1998, s. 167-174.

19. Matsubayashi, S., Yoshihara, T.: Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study. Eur. Arch. Otorhinolaryngol., 264, 2007, s. 789-785.

20. Monteiro, L. S., Bento, M., Palmeira, C. et al.: Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J. Oral. Pathol. Med., 38, 2009, s. 508-513.

21. Normanno, N., De Luca, A., Bianco, C. et al.: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366, 2006, s. 2-16.

22. Prenen, H., Kimpe, M., Nuyts, S.: Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets. Curr. Opin. Oncol., 20, 2008, s. 270-274.

23. Salomon, D. S., Brandt, R., Ciardiello, F. et al.: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 19, 1995, s. 183-232.

24. Shang, J., Shui, Y., Sheng, L. et al: Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for target therapy. Oncol. Rep., 19, 2008, s. 435-440.

25. Sequieros-Santiago, G., Garcia-Carracedo, D., Fresno, M. F. et al.: Oncogene amplification pattern in adenoid cystic carcinoma of the salivary glands. Oncol. Reports, 21, 2009, č. 5, s. 1215-1222.

26. Skálová, A., Stárek, I., Vaněček, T. et al.: Expression of HER2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluoresence in situ hybridisation immunohistochemistry. Histopathol., 42, 2003, č. 4, s. 348-356.

27. Skálová, A., Vaněček, T., Šíma, R. et al.: Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Amer. J. Surg. Pathol., 34, 2010, s. 599-608.

28. Sorensen, K. B., Godballe, C., de Stricker, K. et al.: Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J. Oral Pathol. Med., 35, 2006, s. 286-291.

29. Vered, M., Braunstein, E., Buchner, A.: Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck, 24, 2002, s. 632-636.

30. Vidal, L., Tsao, M. S., Pond, G. R. et al.: Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck, 31, 2009, s. 1006-1012.

31. Wang, L., Gao, Y., Yang, L.: Significance of expression of epidermal growth factor receptor, transforming growth factor beta, c-erbB-2 oncogene in myoepithelioma of salivary gland. Chung-Hua Kou Chiang Hsueh Tsa Chih Chinese J. Stomatol., 34, 1999, č. 2, s. 100-102.

32. Williams, M. D., Robert, D., Blumenschein, G. R. et al.: Differential expression of hormonal and growth factor receptors in salivary duct carcinomas. Amer. J. Surg. Pathol., 31, 2007, s. 1645-1652.

33. Yamada, K., Iwai, K., Okada, Y. et al.: Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch. A Pathol. Anat. Histopathol., 415, 1989, s. 523-531.